Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

S030 - Therapeutic Hotline

Saturday, February 17; 1:00 PM - 4:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Utilize new therapeutics in treating patients with psoriasis, actinic keratoses, acne, rosacea, nail diseases, dyspigmentation, and hair disorders.
  • List new therapeutics for melanoma patients and recognize situations when they are required.
  • Identify and analyze newer research paradigms to treat common medical dermatological conditions with new cutting edge therapies


This session will review new and emerging therapeutics for patients with psoriasis, melanoma, actinic keratoses, acne, rosacea, dyspigmentation, hair diseases, nail disorders, and non-melanoma skin cancer. The newest and what's hot in dermatology ranging from medical to cosmetic to surgical dermatology will be addressed, and in one 3 hour session, virtually the entire spectrum of dermatology will be covered. There will also be a discussion on sunscreens, and selecting the best photoprotection for UVA and UVB coverage.


  • Baldwin, Hilary E., MD: Allergan, Inc. – A(H); Bayer – SP(NC); Dermira – I(Grants/Research Funding); Galderma Laboratories, L.P. – SP(H); Novan – I(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – SP(H); Valeant Pharmaceuticals International – SP(H);
  • Desai, Seemal R., MD: AbbVie – C(Fees), I(Grants/Research Funding); Allergan, Inc – C(Fees); Cassiopea SpA – C(H); Dermira – I(Grants/Research Funding); Dr. Reddy – I(Grants/Research Funding); Ferndale Laboratories, Inc. – A(Fees); Galderma Laboratories, LP – C(Fees); Menlo Therapeutics – C(H), I(Grants/Research Funding); Or-Genix, Therapeutics – C(H); Ortho Dermatologics – C(H), SP(H); Pfizer Inc. – SP(H); Ralexar Therapeutics, Inc – I(Grants/Research Funding); SkinCeuticals LLC – C(H); Symbio – I(Grants/Research Funding);
  • Grimes, Pearl E., MD: Allergan, Inc. – C(H), I(Grants/Research Funding); Clinuvel – I(H); Derm Tech International – I(H); Galderma Laboratories, L.P. – C(Grants/Research Funding), C(H); Incyte Corporation – I(Grants/Research Funding); Kythera – I(H); Laseroptek USA – I(Grants/Research Funding); Merz Pharmaceuticals, LLC – I(Grants/Research Funding); Obagi Medical Products – I(H); Procter & Gamble Company – C(H); Suneva Medical, Inc. – I(H); VT Technologies – I(Grants/Research Funding);
  • Lebwohl, Mark, MD: AbbVie – I(Grants/Research Funding); Allergan, Inc. – C(H); Almirall – C(H); Amgen – I(Grants/Research Funding); Arcutis, Inc. – C(H); AstraZeneca – I(Grants/Research Funding); Boehringer Ingelheim – C(H), I(Grants/Research Funding); Bristol-Myers Squibb – C(H); Celgene Corporation – I(Grants/Research Funding); Clinuvel – I(Grants/Research Funding); Corrona, Inc. – O(H); Dr. Reddy – C(H); Eli Lilly and Company – I(Grants/Research Funding); Foundation for Research & Education of Dermatology – O(H); Incyte Corporation – I(Grants/Research Funding); Janssen Research & Development, LLC – I(Grants/Research Funding); Kadmon Corporation, LLC – I(Grants/Research Funding); Leo Pharma Inc – C(H); LEO Pharma, US – I(Grants/Research Funding); Medimmune – I(Grants/Research Funding); Menlo Therapeutics – C(H); Mitsibushi Pharma – C(H); Neuroderm LTD – C(H); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Ortho Dermatologics – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); SCIderm – I(Grants/Research Funding); Theravance Biopharma – C(H); UCB – I(Grants/Research Funding); Verrica Pharmaceuticals Inc – C(H); Vidac Pharma – I(Grants/Research Funding);
  • Rigel, Darrell S., MD: Aclaris Therapeutics, Inc. – C(H); Beiersdorf, Inc. – A(H); Castle Biosciences – A(H), I(Grants/Research Funding); Derm Tech International – A(H), C(H); Ferndale Laboratories, Inc. – C(H); Foamix – SH(SO); LEO Pharma, US – A(H); Myriad Genetics Inc – A(H); Novartis – A(H); Ortho Dermatologics – A(H); Pierre Fabre Dermo-Cosmétique US – A(H); SciBASE – C(H);
  • Rosen, Theodore, MD: Medimetriks Pharmaceuticals, Inc. – C(H); Menlo Therapeutics – A(H); Valeant Pharmaceuticals International – C(H);
  • Shapiro, Jerry, MD: Aclaris Therapeutics Inc. – A(H); Allergan, Inc. – A(H); Applied Biology – C(H); Bayer Consumer Healthcare Pharmaceuticals – C(NC); Bioniz Therapeutics – A(Fees); Cassiopea SpA – A(NC); Incyte Corporation – C(NC); Johnson & Johnson Consumer Products Company – C(H); L'Oréal France – C(H); RegenLab – I(Grants/Research Funding); RepliCel Life Sciences – F(ST); Samumed, LLC – A(H);
  • Sundaram, Hema A., MD: Allergan, Inc – C(H); Allergan, Inc. – SH(NC); Almirall – C(H); Biopelle, Inc. – C(H), I(Grants/Research Funding); Daewoong Pharmaceuticals – C(H); Eclipse Medical – C(EQ); Evolus, Inc. – I(Grants/Research Funding); Galderma USA – I(Grants/Research Funding); Hugel – C(H); IBSA – C(H); Menarini Group – C(H); Merz Aesthetics – C(H), I(Grants/Research Funding); Recros Medica – C(H), I(Grants/Research Funding); SkinCeuticals LLC – C(H); Strathspey Crown – SH(NC); Syneron, Inc. – C(H); TEOXANE Laboratories – C(H), I(Grants/Research Funding);
  • Tosti, Antonella, MD: Aclaris Therapeutics, Inc. – A(H); Anacor Pharmaceuticals, Inc. – A(H); DS Laboratories – C(Fees); Fotofinder – C(EQ); Incyte Corporation – C(H); Kurt Wolff GmbH & Co. KG – A(H); Kythera – A(H); Meiji Seika Pharma Co., Ltd – A(H); MSD – SP(H); Novartis – A(H); PharmaDerm – Speaker/Faculty Education(H); Pierre Fabre Dermatologie – C(H); Polichem SA – A(H); Procter & Gamble Company – A(H); Springer Science & Business Media – O(IP); Taylor & Francis – O(IP); topica – C(Fees); Valeant Pharmaceuticals International – C(Fees); Viamet Pharmaceuticals, Inc – A(H);
Saturday, February 17
1:00 PM
Dr. Desai / Welcome and Introduction
1:03 PM
Dr. Shapiro / What's New in Hair Disorders
1:20 PM
Dr. Rosen / What's New in Infectious Diseases
1:38 PM
Dr. Sundaram / What’s New in Aesthetic Therapeutics
1:55 PM
Dr. Baldwin / What's New in Acne and Rosacea
2:15 PM
Dr. Rosen, Dr. Shapiro, Dr. Sundaram, and Dr. Baldwin / Panel: Questions And Discussion
2:30 PM
Dr. Rigel / What's New in Skin Cancer
2:50 PM
Dr. Grimes / What's New in Pigmentary Disorders
3:10 PM
Dr. Tosti / What's New in Nail Disorders
3:25 PM
Dr. Lebwohl / What’s New in Psoriasis
3:45 PM
Dr. Lebwohl, Dr. Rigel, Dr. Grimes, and Dr. Tosti / Panel: Questions And Discussion
Event Details
  • Date
    Saturday, February 17
  • Time
    1:00 PM - 4:00 PM
  • Location
    Room 3
  • CME Credits
  • Type
  • Seemal R. Desai, MD, FAAD
  • Antonella Tosti, MD - Handout
  • Darrell S. Rigel, MD, FAAD - Handout
  • Hema A. Sundaram, MD, FAAD
  • Hilary E. Baldwin, MD, FAAD
  • Jerry Shapiro, MD, FAAD
  • Mark Lebwohl, MD, FAAD - Handout
  • Pearl E. Grimes, MD, FAAD
  • Theodore Rosen, MD, FAAD - Handout